FDA Approves Plozasiran for Familial Chylomicronemia Syndrome, Marking Breakthrough in Rare Lipid Disorder Treatment
核心洞察
The FDA approved plozasiran on November 18, 2025, as the first RNA interference therapeutic for reducing triglycerides in adults with familial chylomicronemia syndrome (搜索).
The PALISADE phase 3 trial demonstrated an 80% median reduction in triglycerides and an 83% decreased risk of acute pancreatitis (搜索) compared to placebo.
Plozasiran represents a targeted therapy for a historically underserved patient population with limited treatment options.
The US Food and Drug Administration approved plozasiran on November 18, 2025, for the reduction of triglycerides in adult patients with familial chylomicronemia syndrome (搜索) (FCS), marking a significant breakthrough for patients with this rare lipid disorder. Developed by Arrowhead Pharmaceuticals, plozasiran represents the first-in-class RNA interference therapeutic designed to reduce the production of apoC-III (搜索), a major component of triglyceride-rich lipoproteins and a regulator of triglyceride metabolism.
Clinical Trial Results Drive Approval
The FDA approval was based on the PALISADE phase 3 trial, which demonstrated statistically significant reductions in apoC-III (搜索), triglycerides, and acute pancreatitis (搜索) incidence. Patients receiving plozasiran exhibited an 80% median change in triglycerides from baseline and an 83% decreased risk of acute pancreatitis compared to placebo. The drug is now available for sale in the United States.
According to Christie Ballantyne, MD, chief of cardiovascular research at Baylor College of Medicine and principal investigator in the PALISADE trial, the approval represents a turning point for FCS management. "2025 marks a turning point for FCS, with the approval of plozasiran on November 18 and olezarsen's approval in late 2024 providing targeted therapies capable of substantially reducing triglycerides," Ballantyne noted.
Addressing Unmet Medical Needs
Familial chylomicronemia syndrome (搜索) has historically been an underserved condition with limited treatment options. The approval of plozasiran expands treatment options for this patient population, providing a targeted therapy that modulates pathways independent of lipoprotein lipase activity.
Ballantyne discussed the mechanism of action of small interfering RNA therapies like plozasiran and how they represent a novel approach to managing this rare lipid disorder. The therapy works by reducing the production of apoC-III (搜索), which plays a crucial role in triglyceride metabolism and clearance.
Broader Context in Lipid Management
The approval of plozasiran comes during a year of significant advances in lipid management. 2025 has seen key FDA approvals including inclisiran's label update for first-line monotherapy in hypercholesterolemia (搜索) and lerodalcibep-liga (搜索) (Lerochol) for LDL-C reduction. These developments, along with major trial advances of olezarsen and enlicitide, have provided new resources for historically underserved populations in lipid disorders.
The therapeutic landscape for rare lipid disorders has been transformed with targeted therapies that offer substantial triglyceride reductions and improved clinical outcomes for patients with familial chylomicronemia syndrome (搜索).